An observational study in Heart Failure and Cardiac Resynchronisation Therapy, sponsored by National University Heart Centre, Singapore. Recruiting at 1 site in Singapore. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-09.
Sponsored by National University Heart Centre, Singapore · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 62 studies in Heart Failure with a site in Singapore — 6 open to participants now, 14 under way, 2 of them phase 3. Heart Failure · Singapore.
Among the 62 studies in Heart Failure with a site in Singapore, this one is the 10th largest by planned enrollment of the 16 observational ones that give a count, is one of 2 that started in 2011, is one of 16 observational ones, reaches primary completion later than 12 of the 13 other live ones, and was the 28th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →6 of the 62 studies in Heart Failure with a site in Singapore are open now. Recruiting first, the newest first:
Abbott Medical Devices · Sites in Singapore, Brazil, France and 6 more countries
Ages 18+
National Heart Centre Singapore · Sites in Singapore
Ages 21–99 · Healthy volunteers
National Cancer Centre, Singapore · Sites in Singapore
Ages 21–99
Merck Sharp & Dohme LLC · Sites in Singapore, United States, Belgium and 27 more countries
Ages 29 days–17 yrs
National University Hospital, Singapore · Sites in Singapore
Ages 40–99
A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
62 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 10 · Phase 3 17 · Phase 4 4
First in 2006; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 200 across 1,987 observational studies indexed under Heart Failure.
Median enrollment 310 across the 46 interventional studies, 678 across the 16 observational. Of the 45 that completed or were terminated, 27 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 62 have an industry lead sponsor. The 10 most frequent:
National University Heart Centre, Singapore is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
National University Heart Centre, Singapore has 1 study filed under Heart Failure — fewer than ten, so there is no comparison to draw.
3 of the studies in Heart Failure with a site in Singapore that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05374291Phase 3University Medical Center GroningenThe RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | 2027-07 |
| NCT06090734Duke-NUS Graduate Medical SchoolDevelopment and Evaluation of 'My Voice': A Randomized Controlled Trial | 2027-03 |
| NCT07217392Abbott Medical DevicesLeft Bundle Branch Area Pacing (LBBAP) PMCF Study | 2027-04-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 62 studies in Heart Failure with a site in Singapore, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Aim:To determine the baseline characteristics of heart failure patients in Singapore undergoing cardiac resynchronization therapy (CRT); the long term outcome and predictors of response to CRT.
Methodology:Among patients undergoing CRT for severe heart failure according to indications stipulated in international Cardiology guidelines, baseline demographic data is collected. Age, gender, NYHA functional class, co-morbidities, QRS width on ECG, presence of left bundle branch block pattern on ECG, presence of atrial fibrillation, left ventricular ejection fraction (LVEF) on echocardiogram, ventricular dimensions, 6 min walk test distance are collected. In addition, during the CRT implant procedure, blood is drawn from the vascular access and analysed for NT-pro BNP levels and other biomarkers of heart failure.
The echocardiographic and ECG parameters and blood biomarkers are reanalysed at 6 months and 12 months following CRT implant. Response to CRT is defined as a reduction in the iLVESV (left ventricular end-systolic volume index to body surface area) of >/= 15% and/or an increase in the LVEF of >/= 10%.
Among patients undergoing CRT for severe heart failure according to indications stipulated in international Cardiology guidelines, baseline demographic data is collected. Age, gender, NYHA functional class, comorbidities, QRS width on ECG, presence of left bundle branch block pattern on ECG, presence of atrial fibrillation, left ventricular ejection fraction (LVEF) on echocardiogram, ventricular dimensions, 6 min walk test distance are collected. In addition, during the CRT implant procedure, blood is drawn from the vascular access and analysed for NT-pro BNP levels and other biomarkers of heart failure. The echocardiographic and ECG parameters and blood biomarkers are reanalysed at 6 months and 12 months following CRT implant. Response to CRT is defined as a reduction in the iLVESV (left ventricular end-systolic volume index to body surface area) of >/= 15% and/or an increase in the LVEF of >/= 10%.
Singaporean patients with broad QRS complexes, EF \<40%, heart failure, requiring CRT
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Heart failure patients with QRS \> 120ms receiving CRT
Device: Cardiac Resynchronization Therapy
Cardiac resynchronization therapy with or without ICD
Echocardiographic response to CRT
A subject is considered an echocardiographic responder to CRT if there is: 1. reduction in the iLVESV (left ventricular end-systolic volume index to body surface area) of \>/= 15% OR 2. an increase in the LVEF of \>/= 10% during follow-up echocardiography at 6 months
Time frame: 6 months
Neuroendocrine response to CRT
A subject is considered to have a neuro-endocrine response to CRT if BNP levels at 6 months post CRT implant has fallen more than 30% from baseline
Time frame: 6 months
Clinical response to CRT
A subject is considered a positive clinical responder to CRT if: 1. NYHA class has improved by at least 1 class OR 2. 6 minutes walking test has increased by at least 10%
Time frame: 6 months
Hospitalization For Cardiovascular events
Hospitalisation for acute coronary syndrome, heart failure, arrhythmias, ICD shocks or any unplanned admissions for any cardiac interventions or surgery
Time frame: 8 years
Mortality
Mortality
Time frame: 8 years
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Jan 2011, a primary completion of Dec 2030 and a completion of Dec 2030. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National University Heart Centre, Singapore